Malignant Solid Tumors
Conditions
Interventions
Experimental group:chemotherapy plus ABES
Control group:chemotherapy
Sponsors
Daping Hospital, Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. All patients with malignant solid tumors requiring more than two drugs of chemotherapy; 2. Previous history of at least grade 1 of thrombocytopenia after chemotherapy or chemotherapy with GP regimen (gemcitabine plus platinum); 3. Performance status of 0, 1 on the ECOG criteria; 4. Patients without oral contraindications; 5. Patient compliance that allow adequate follow-up: Adequate hematologic (neutrophil count >= 1,500/uL, platelets >= 100,000/uL), hepatic (transaminase =< upper normal limit(UNL)x2.5, bilirubin level =< UNLx1.5), and renal (creatinine =< UNL) function 6. Informed consent from patient or patient's relative.
Exclusion criteria
Exclusion criteria: 1. Patients with with interior heat and yin deficiency syndrome; 2. Patients who received radiotherapy in the past month; 3. Patients with concurrent radiotherapy and chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| grade of thrombocytopenia; | — |
Secondary
| Measure | Time frame |
|---|---|
| grade of leukopenia;grade of anemia;rate of platelet transfusion;objective response rate;delay rate of chemotherapy;reduction rate of chemotherapy dose;Medical expenses of patients; | — |
Countries
China
Contacts
Public ContactXueqin Yang
Cancer Center, Daping Hospital, Army Medical University
Outcome results
None listed